Results

1–10 of 21 results for Phase 1

Interim Subretinal Gene Therapy Safety Results in Two Phase 1/2 Open-label, Dose-Escalation Clinical Trials to Treat Achromatopsia
Lejla Vajzovic, MD, FASRS
Annual Meeting Talks
2022
ADVM-022 Intravitreal Gene Therapy for Neovascular AMD: Phase 1 OPTIC Trial Update
Dante Joseph Pieramici, MD
Annual Meeting Talks
2022
THR-687, a Highly Selective RGD Integrin Inhibitor, for the Treatment of Diabetic Macular Edema: Preclinical, Phase 1 and Preliminary Phase 2 (Part A) Data
On Demand Cases, Courses, and Papers
2022
A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD
Vrinda S. Hershberger, MD, PhD
On Demand Cases, Courses, and Papers
2021
Intravitreal Gene Therapy for Neovascular AMD with ADVM-022: Results of the Phase 1 OPTIC Trial
Dante Joseph Pieramici, MD
Annual Meeting Talks
2021
APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies
Michael J Allingham, MD, PhD
Annual Meeting Talks
2021
AAV-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa: 6-month Results From a Phase 1/2 Clinical Trial
Michel Michaelides, BSc, MB BS, MD(Res), FRCOphth, FACS
Annual Meeting Talks
2020
Update From an Ongoing Phase 1b/2 Open-label Clinical Trial Evaluating the Safety and Efficacy of AU-011 for the Treatment of Choroidal Melanoma
Ivana K. Kim, MD
Annual Meeting Talks
2020
Phase 1 Safety Study of Intravitreal (ITV) Anti-High Temperature Requirement A1 (aHtrA1), a Novel Serine Protease Inhibitor, in Patients With GA
William Z. Bridges, MD
Annual Meeting Talks
2020
Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD
Robert L. Avery, MD
Updates from the Field
2021